Mobile website
Clinical Research
Clinical effectiveness of autologous tumor antigen-pulsed dendritic cell-cytokine induced killer cells combined with chemotherapy in treatment of advanced lung adenocarcinoma
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Objective:To investigate the clinical efficacy and safety of autologous tumor antigen-pulsed DC-CIK (dendritic cell-cytokine induced killer cell) combined with chemotherapy in treatment of advanced lung adenocarcinoma.Methods: 120 patients with advanced lung adenocarcinoma treated in the Affiliated Tumor Hospital of Xinjiang Medical University from Jan 2013 to December 2013 were selected in this study; 60 patients were treated with autologous tumor antigen-pulsed DC-CIK combined with chemotherapy (combination group), the other 60 patients were treated with chemotherapy only (chemotherapy group); the immune function, curative effect, adverse reactions, quality of life (QOL), progression free survival (PFS) and overall survival (OS) after treatment were separately evaluated in the two groups . Results: Compared to the values of pre-treatment, there was no significant difference in peripheral blood T cell subsets in combination group (P>0.05); Compared to pre-treatment value, the post-treatment percentage of CD3+, CD3+CD4+, CD3+CD8+ and CD3-CD56+ in peripheral blood decreased significantly in chemotherapy group, and it was significant lower than that of combination group (P<0.05); the incidences of nausea and vomiting, Ⅲ-Ⅳ degree myelosuppression in combination group were less than that of chemotherapy group, and the difference was statistically significant (P<005); after treatment, compared with chemotherapy group, the combination of sleep, appetite and physical strength in combination group was significantly improved (P<0.05). There was no significant difference in PFS between combination group and chemotherapy group (6 months vs 4.5 months, P>0.05), however, the OS of combination group was longer than that of chemotherapy group (16 months vs 11.5 months, P<0.05). Conclusion:Autologous tumor antigen-pulsed DC-CIK combination with chemotherapy, compared with chemotherapy alone, can obviously optimize the immune function of the patients, improve their life quality, reduce the adverse reactions, prolonged overall survival periods, and improve the overall curative effects.
Keywords:
Project Supported:
Project supported by Wu Jieping Medical Foundation(No. 320675012239), and the Xinjiang Medical University Scientific Research Innovation Foundation（No. XYDCX201485）
Clc Number:
